Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 7/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.58 |
| ▸ | HTR3B | O95264 | 1/20 | 0.58 |
| ▸ | HTR5A | P47898 | 1/20 | 0.58 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.58 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7358591 | 0.88 | HTR3A (0.59) | HTR3ACYP2C9CYP2C19HTR3EHTR3B | |
| SCHEMBL7358583 | 0.88 | HTR3A (0.59) | HTR3ACYP2C9CYP2C19HTR3EHTR3B | |
| SCHEMBL10436140 | 0.87 | HTR3A (0.67) | HTR3ACYP2C9CYP2C19HTR3EHTR3B | |
| SCHEMBL7359887 | 0.81 | HTR3A (0.55) | HTR3ACYP2C9CYP2C19HTR3EHTR3B | |
| SCHEMBL7362425 | 0.80 | HTR3A (0.51) | HTR3ACYP2C9CYP2C19HTR3EHTR3B | |
| SCHEMBL2228529 | 0.80 | HTR3A (0.69) | HTR3ACYP2C9CYP2C19HTR3EHTR3B | |
| SCHEMBL2228533 | 0.80 | HTR3A (0.69) | HTR3ACYP2C9CYP2C19HTR3EHTR3B | |
| SCHEMBL7292105 | 0.80 | HTR3A (0.69) | HTR3ACYP2C9CYP2C19HTR3EHTR3B | |
| SCHEMBL7362879 | 0.79 | HTR3A (0.57) | HTR3ACYP2C9CYP2C19HTR3EHTR3B | |
| SCHEMBL7396664 | 0.79 | HTR3A (0.55) | HTR3ACYP2C9CYP2C19HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | SWITCH BIO, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20240317834-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2024-09-26 | — | — | US | disclosed |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | TRAMES BIO, INC. | 2022-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152742-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | HTR3A 1705/4885CYP2C9 4860/4885CYP2C19 4849/4885 |
| US-20250163130-A1 | LIGAND GATED ION CHANNELS AND METHODS OF USE | CACNB2, CHRNA2, HCN3 | HTR3A 975/4885CYP2C9 4837/4885CYP2C19 4842/4885 |
| US-20240317834-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | HTR3A 1705/4885CYP2C9 4860/4885CYP2C19 4849/4885 |
| US-20220348635-A1 | COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES | CHRNB2, CHRNA2, CHRNA6 | HTR3A 1705/4885CYP2C9 4860/4885CYP2C19 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.